MedTrace Logo

Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery

NCT06290193 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2026-04-01

No results posted yet for this study

Summary

Participants will be scheduled for primary cytoreductive surgery as part of their standard care. Before surgery, participants will be assigned by chance to a study group. Depending on which group they are in, they will receive either acute normovolemic hemodilution/ANH during surgery or standard surgical management during surgery. The researchers think acute normovolemic hemodilution/ANH may decrease the need for allogenic blood transfusion/ABT in people having primary cytoreductive surgery.

Conditions

  • Ovarian Cancer
  • Fallopian Tube Carcinoma
  • Ovarian Carcinoma
  • Peritoneal Carcinoma
  • Ovarian Cancer Stage IIIC
  • Fallopian Tube Cancer Stage IIIC
  • Ovarian Cancer Stage IV
  • Fallopian Tube Cancer Stage IV
  • Fallopian Tube Cancer
  • Peritoneal Cancer

Interventions

BIOLOGICAL

Acute Normovolemic Hemodilution/ANH

For participants randomized to ANH, the volume of blood to be removed will be calculated using an established formula, based on preoperative hemoglobin, target hemoglobin after hemodilution, and the patient's estimated blood volume.

Sponsors & Collaborators

Principal Investigators

  • Dennis Chi, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-23
Primary Completion
2029-02-23
Completion
2029-02-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06290193 on ClinicalTrials.gov